Recruiting studies: Hepatic Impairment Hi

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Phase 1 · 2 location(s) · Edgewise Therapeutics, Inc. · NCT07324616 Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 1 · 8 location(s) · Novartis Pharmaceuticals · NCT07422610 Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Phase 1 · 2 location(s) · Exelixis · NCT06962332 A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Phase 1 · 3 location(s) · Merck Sharp & Dohme LLC · NCT06442436 A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
Phase 1 · 1 location(s) · InventisBio Co., Ltd · NCT07715149 Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
Phase 1 · 3 location(s) · Zealand Pharma · NCT07682818

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.